Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen
Clinical trial NCT03333083 · TERMINATED
Trial details
- NCT number
- NCT03333083
- Sponsor
- Judit Pich
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-05-03
- Primary completion
- 2020-06-25
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.